Synta Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synta Pharmaceuticals

SNTA 0.343

+26.6%

Jul 22 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (2)	8/10/2007 1:21:55 PM
From: tuck	Read Replies (2) of 112

Believe lock-up expiration just happened, but no recent form 4s. Market cap stands ~$230 million, which approximates your valuation analysis. But . . . missed the 1st half target for IND of 9090, now supposed to be this quarter. 4783 expected to enroll in metastatic melanoma in 3rd q as well, which represents a very slight pushout from mid-year. Obviously been beaten up on these little delays and need for secondary within a year (probably more like 6 months). Thinking a half position now, with impending news of 4783 starting limiting further downside, and another a half position after they announce the financing . . . or whatever full position one is comfortable with now, sell all in autumn, buy back after secondary. I like the latter plan at the moment. Anyone else got current thoughts? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next